CANCER DRIVER INTERCEPTION, Systemic Inflammation, Gut Dysbiosis, Genomic Instability, Immune System Deficiency, PRENATAL SCREENING, G-TEST, ULTRANIPT , ULTRANIPT DG, OMNIPT, Inherited Metabolic Disorder, Severe Combined Immunodeficiency, Lysosomal Storage Diseases, CANCER EARLY DETECTION, Solid Cancer, Breast and Ovary, Lung, Colon and rectum, Genome Instability, AESTHETICS STEM CELLS, Skin Rejuvenation, Face Reshaping, Breast augmentation, Buttock enhancement, Scar Reduction, Hair Loss, Female rejuvenation, Penis enlargment, HEREDITARY CANCERS DRIVERS, Endometrium, Colon, Solid Cancers, Breast and Ovary, REGENERATIVE STEM CELLS, Orthopedics, Premature Ovarian Failure, Erectile dysfunction, Anti-aging Therapy iV, Empty Nose Syndrome, Body Performance, Supportive Care, CANCER DIAGNOSIS, Colon and Rectum, Breast, Ovary and Prostate, Lung Cancer Assay, Liquid Biopsy, STEM CELL EXOSOMES, Skin Aging, Hair Loss, Orthopedics, Erectile Dysfunction, Female Rejuvenation, Body Performance, Anti-Ageing, PREVENTIVE CANCER THERAPY, Systemic Inflammation, Dysbiosis, Genomic Instability, Immune Deficiency, STEM CELL BANKING, Cord Blood Derived, Cord Tissue Derived, Adipose Tissue Derived, EXOSOME COSMETICS, X-FILL – Eye & Lip Contour, X-LIFT – Firm Facial Lifting, X-SKIN- Advanced Moisturizing, X-HAIR – Hair Loss Treatment

Oncogenetic

By yearly monitoring the occurrence of cancer-associated mutations in asymptomatic patients, we can potentially detect the solid cancer prodromal stage, before a clear clinical manifestation. It now acquired that it might take several years between the appearance of a first mutation and the actual development of cancer. Thus, the detection of certain mutations driving the early identification of neoplastic lesions can significantly improve survival rates.
Current diagnostic methods (such as mammography, X-rays, colonoscopy and dermoscopy) detect cancers when they already exist as established tumor. Identifying the cancer-associated mutations as soon as they occur and before tumor is detectable with current diagnostic methods may enable the full eradication of the disease and significantly better outcome for the patient.

A SOMATIC mutation is not present in the zygote, but is acquired during a patient’s life as a consequence to various factors, such as dangerous environment agents or life-style behavior (e.g. cigarette smoke).
SOMATIC mutations may occur in a single cell that by sub sequentially acquiring a proliferative advantage leading to multiple and sustained rounds of cell divisions will carrying on these mutations along in all ‘offspring’ cells.
Nonetheless since SOMATIC mutations are not hereditary, they are not passed onto future generations.
Most cancers result from the accumulation of acquired (SOMATIC) mutations because they are more common than their germline (inherited) counterpart.

MUTATIONS AND GENETIC INSTABILITY

ARE INDICATORS IN CANCER RISK

Environmental and lifestyle factors such as smoking, poor and fat-rich diet, hormone imbalance and radiation/sun exposure can lead to the acquisition of SOMATIC mutations in cancer-relevant genes.
Occasionally, random mutations occur during cell division, seemingly without cause. During normal cell division, the original cell must replicate its DNA; such process leads to occasional errors and the introduction of mutations within the DNA sequence.

Although our cells have developed a highly sophisticated and efficient DNA replication proofreading system, every cell division represents an new opportunity for a mutation to occur. Usually, healthy cells detect mutations in their DNA sequence and promptly repair them. If particular mutation cannot be repaired, the cell turns up a cell death guided process called apoptosis.

However, if cell death does not occur and the mutation is not repaired, the cell might start dividing and eventually leading to cancer. As we get older, the number of somatic mutations accumulates and our DNA replication proofreading system reduces its efficiency, that is why age poses a greater risk of developing cancer.

Precision medicine is an approach that allows physicians to select treatments based on the genetic abnormalities of each individual patient.
Currently, patients diagnosed with cancer usually receive the same standard of care treatment as others who have the same cancer type or subtype.
As a consequence, not all patients respond equally to a given treatment, and many patients are given sub-optimal therapies.
In contrast, with a precision medicine approach, the mutational profile of each patient serves as a reference for treatment decisions, and allows clinicians to identify the best treatment for each patient.

×

Information Request








    Privacy Policy (*)